LP
GTHX

LMR Partners’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

LMR Partners’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,216
Closed -$61.4K – 1366
2024
Q1 		$61.4K Buy
+14,216
New +$49.5K ﹤0.01% 969
2022
Q4 		– Sell
-14,133
Closed -$177K – 1332
2022
Q3 		$177K Hold
14,133
– – ﹤0.01% 1024
2022
Q2 		$70K Buy
+14,133
New +$78.3K ﹤0.01% 1130

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners's GTHX Position: Q2 2024 in Review

LMR Partners sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 14,216 shares — an estimated $61.4K sold.

LMR Partners first reported a position in GTHX in Q2 2022 and held it in 3 quarters. The position peaked at $177K in Q3 2022. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • LMR Partners reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 14,216 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $61.4K.
  • LMR Partners first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • LMR Partners's G1 Therapeutics, Inc. Common Stock position peaked at $177K in Q3 2022.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.